Share this PR

Press Contact

Infinium Global Research

Infinium Global Research



Contact Email

Social Media

Exocrine Pancreatic Insufficiency Market: Global Product Intelligence, Analysis, Opportunities and Forecast to 2023

PressReleasePing - November 13, 2017 -Infinium Global Research has added a new report on Global Exocrine Pancreatic Insufficiency Market. The report predicts the market size of Exocrine Pancreatic Insufficiency is expected to reach XX billion by 2022. Exocrine Pancreatic Insufficiency (EPI) is a serious digestive problem and caused by improper digestion, and exocrine pancreatic insufficiency. It is a kind of a chronic disease caused by deficiency in pancreatic enzyme. Global revenue of exocrine pancreatic insufficiency market, was valued at more than USD 700 million in 2015, and is projected to surpass USD X.X Billion by 2023. Furthermore, the global exocrine pancreatic market is anticipated to grow at a CAGR between 8.0% – 8.6% over the period of 2017 to 2023. Increasing global incidences for exocrine pancreatic insufficiency is one of the prime reasons increasing demand of advanced therapeutics globally. Furthermore, presence of significant number of pipeline drugs and lipase treatment in diabetic patients, optimizes the chymotrypsin and trypsin level are expected to drive the global market for exocrine pancreatic insufficiency market over the forecast period. Moreover, the EPI market has been segmented by the mode of disease management, therapeutics drugs, diagnostic tests and geography. Mode of disease management contains nutrition management, PERT. Therapeutics drugs consist Creon, Zenpep, Pancreaze, Ultresa and Pertzye. Get a Sample Report @ The report covers the analysis of exocrine pancreatic insufficiency market by therapeutics and diagnostic tests. Furthermore, the report covers the analysis of global as well as regional markets of exocrine pancreatic insufficiency. North America dominated the global market of exocrine pancreatic insufficiency by accounting for the largest market share. While the Asia Pacific region is expected to grow at a highest CAGR over the forecast period 2017 – 2023. Moreover, the report provides deep insights on demand forecasts, market trends and micro and macro indicators. In addition, this report provides insights on the factors that are driving and restraining the demand globally as well as regionally. Moreover, Infinium Global Research- Growth Matrix analysis given in the report brings an insight on the investment areas that existing or new market players can consider. Company profile Abbvie Inc. Allergan plc. Nordmark Arzneimittel GmbH & Co. KG Digestive Care, Inc. Cilian AG Anthera Pharmaceuticals Inc. Janssen Pharmaceuticals Inc. AzurRx BioPharma Inc. Make an Enquiry @ Key topics covered: 1. Preface 2. Executive summary 3. Exocrine pancreatic insufficiency industry analysis 4. Exocrine pancreatic insufficiency regulatory aspects 5. Exocrine Pancreatic Insufficiency Market by Disease Management 6. Exocrine Pancreatic Insufficiency Market By Therapeutics Drugs 7. Exocrine Pancreatic Insufficiency Market By Diagnosis 8. Exocrine Pancreatic Insufficiency Market By Geography 9. Company profile Click to View Complete Report @

Creative Commons License

This press release is licensed under a Creative Commons Attribution 3.0 Unported License.